Skip to main content
. 2022 May 13;13:898815. doi: 10.3389/fmicb.2022.898815

Figure 3.

Figure 3

Capsule affects pneumococcal resistance do indolicidin. Wild-type pneumococcal strains D39 (serotype 2) and TIGR4 (serotype 4) and their capsule-negative mutants AM1001 (D39 background) and HR1001 (TIGR background) were treated with indolicidin at 15 μg/ml (A) and 30 μg/ml (B) and plated. The percent reduction in bacterial survival is shown for each group. Statistical analysis was performed using Student’s t-test. *p < 0.05 in comparison with the wild-type strain; ns, not significant.